dexmedetomidine has been researched along with Liver Dysfunction in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, H; Jia, L; Lyu, J; Sheng, M; Yu, H; Yu, W | 1 |
| Cheng, G; Li, Y; Qiu, G; Wang, Y; Wu, W; Wu, Y; Zhang, H; Zhu, L | 1 |
| Chang, ZN; Guo, Y; Lai, HJ; Liu, ZM; Wen, SH; Zhan, YQ; Zhang, HF; Zhang, XY; Zhang, YN | 1 |
| Ao, X; Chen, DD; Deng, C; Li, JH; Liu, L; Wu, SZ; Zi, SF | 1 |
| Li, GW; Ou, SS; Xiao, XY; Zhou, JH; Zhou, WY; Zhu, YX | 1 |
| Bi, L; Jia, Z; Li, XK; Yang, SC | 1 |
| Aprea, F; Corletto, F; Ferrandis, I; Jakovljevic, S | 1 |
| Deng, LH; Hua, YP; Huang, CY; Huang, WQ; Liu, KX; Wang, ZX | 1 |
| Arslan, M; Elmas, C; Erer, D; Goktas, G; Iriz, E; Oktar, GL; Ozer, A; Tatar, T; Zor, MH | 1 |
| Arslan, M; Cavunt-Bayraktar, A; Comu, FM; Kavutcu, M; Kucuk, A; Tosun, M; Yaylak, F | 1 |
| Ehsan, NA; Elfert, AY; Fayed, NA; Saleh, SM; Sayed, EI | 1 |
| Begeç, Z; Durmuş, M; Ersoy, MÖ; Polat, A; Sahin, T; Toprak, Hİ; Vardi, N; Yücel, A | 1 |
3 trial(s) available for dexmedetomidine and Liver Dysfunction
| Article | Year |
|---|---|
Effect of two sedative protocols and hepatosplenic disease on Doppler indices of splenic arteries in dogs: a preliminary study.
Topics: Acepromazine; Analgesics, Opioid; Animals; Arteries; Butorphanol; Dexmedetomidine; Dog Diseases; Dogs; Dopamine Antagonists; Hypnotics and Sedatives; Liver Diseases; Spleen; Splenic Diseases; Ultrasonography, Doppler | 2013 |
Dexmedetomidine reduces intestinal and hepatic injury after hepatectomy with inflow occlusion under general anaesthesia: a randomized controlled trial.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Analgesics, Non-Narcotic; Anesthesia, General; Biomarkers; Dexmedetomidine; Double-Blind Method; Female; Hepatectomy; Humans; Intestinal Diseases; Intestines; Liver; Liver Diseases; Male; Middle Aged; Prospective Studies; Reperfusion Injury | 2014 |
Effect of dexmedetomidine on hepatic ischemia-reperfusion injury in the setting of adult living donor liver transplantation.
Topics: Adult; Analgesics, Non-Narcotic; Biopsy; Case-Control Studies; Dexmedetomidine; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Liver Diseases; Liver Function Tests; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Complications; Prognosis; Prospective Studies; Protective Agents; Reperfusion Injury; Risk Factors | 2016 |
9 other study(ies) available for dexmedetomidine and Liver Dysfunction
| Article | Year |
|---|---|
Dexmedetomidine Ameliorates Hippocampus Injury and Cognitive Dysfunction Induced by Hepatic Ischemia/Reperfusion by Activating SIRT3-Mediated Mitophagy and Inhibiting Activation of the NLRP3 Inflammasome in Young Rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Cognitive Dysfunction; Dexmedetomidine; Hippocampus; Inflammasomes; Ischemia; Liver; Liver Diseases; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sirtuins | 2020 |
Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway.
Topics: Animals; Biomarkers; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Liver Diseases; NF-E2-Related Factor 2; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphatidylinositol 3-Kinases; Protective Agents; Proto-Oncogene Proteins c-akt; Rats; Reperfusion Injury; Signal Transduction | 2021 |
Dexmedetomidine Alleviates Gut-Vascular Barrier Damage and Distant Hepatic Injury Following Intestinal Ischemia/Reperfusion Injury in Mice.
Topics: Analgesics, Non-Narcotic; Animals; Capillary Permeability; Dexmedetomidine; Human Umbilical Vein Endothelial Cells; Humans; Injections, Intraperitoneal; Intestinal Mucosa; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Reperfusion Injury | 2022 |
Dexmedetomidine-mediated protection against septic liver injury depends on TLR4/MyD88/NF-κB signaling downregulation partly via cholinergic anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Dexmedetomidine; Down-Regulation; Interleukin-6; Lipopolysaccharides; Liver; Liver Diseases; Male; Myeloid Differentiation Factor 88; NF-kappa B; Rats, Sprague-Dawley; Sepsis; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Vagus Nerve | 2019 |
Dexmedetomidine protects liver cell line L-02 from oxygen-glucose deprivation-induced injury by down-regulation of microRNA-711.
Topics: Apoptosis; Cell Hypoxia; Cell Line; Cytokines; Cytoprotection; Dexmedetomidine; Down-Regulation; Glucose; Humans; Ischemia; Janus Kinase 1; Liver; Liver Diseases; MicroRNAs; Oxygen; p38 Mitogen-Activated Protein Kinases; Signal Transduction; STAT3 Transcription Factor | 2018 |
Effects of dexmedetomidine on sepsis-induced liver injury in rats.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Lipopolysaccharides; Liver Diseases; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Random Allocation; Rats; Rats, Sprague-Dawley; Sepsis; Survival Analysis; Treatment Outcome | 2019 |
The protective effects of dexmedetomidine on liver injury-induced myocardial ischemia reperfusion.
Topics: Animals; Coronary Vessels; Dexmedetomidine; Humans; Liver; Liver Diseases; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Protective Agents; Rats; Rats, Wistar | 2014 |
The protective effects of dexmedetomidine on hepatic ischemia reperfusion injury.
Topics: Animals; Dexmedetomidine; Ischemia; Ischemic Preconditioning; Liver; Liver Diseases; Protective Agents; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury | 2014 |
The effects of dexmedetomidine on liver ischemia-reperfusion injury in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Drug Evaluation, Preclinical; Liver; Liver Diseases; Male; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2013 |